Actavis extends exclusive agreement to distribute authorized generic Concerta Actavis has reached an agreement with Janssen Pharmaceuticals to continue supplying the authorized generic version of JPI's Concerta. Under the terms of the extended exclusive agreement originally due to expire on December 31, JPI will continue to manufacture and supply Actavis with all dosage strengths of the authorized generic product, and Actavis will continue to market and distribute the product in the U.S. JPI will receive 50% of the net sales from Actavis' product. The extended agreement runs until December 31, 2017. During the term of the agreement, Actavis may continue to pursue FDA approval of its abbreviated new drug application for a generic version of Concerta and may launch its own ANDA product at the conclusion of the exclusive supply agreement.
News For ACT From The Last 14 Days
Check below for free stories on ACT the last two weeks.